Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
Cabozantinib + Nivolumab + Ipilimumab for Kidney Cancer
Phase 2
Recruiting
Led By Bradley McGregor, MD
Research Sponsored by Bradley A. McGregor, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age ≥ 18 years
ECOG performance status ≤1
Must not have
Bleeding diathesis, or significant coagulopathy in the absence of therapeutic anticoagulation
Prior allogenic stem cell or solid organ transplant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up defined as the percentage of patients with partial (pr) or complete response (cr) as best overall response according to recist 1.1 by investigator assessment up to 21 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a combination of three drugs to see if they can slow down advanced kidney cancer that has spread. The drugs work by stopping cancer growth and helping the immune system attack the cancer. About 40 people will participate in this study.
Who is the study for?
Adults with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) who haven't had certain previous treatments can join. They must be able to provide a fresh tumor biopsy, use contraception, and have normal organ/marrow function. Excluded are those with specific heart diseases, autoimmune conditions, lung fibrosis, bleeding disorders without therapeutic anticoagulation, severe infections or on strong CYP3A4 inhibitors/inducers.
What is being tested?
The trial is testing the combination of Cabozantinib with immunotherapy drugs Nivolumab and Ipilimumab for effectiveness in slowing kidney cancer growth. Participants will receive all three medications to see if they work better together than current standard treatments.
What are the potential side effects?
Possible side effects include liver problems, diarrhea, fatigue, skin rash and itching. There may also be risks of immune-related issues like inflammation in organs such as lungs or intestines and potential hormonal gland problems.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I am fully active and can carry on all pre-disease activities without restriction.
Select...
My kidney cancer cannot be removed by surgery and has spread.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a bleeding disorder not caused by blood thinners.
Select...
I have had a previous transplant of an organ or stem cells from a donor.
Select...
I am not taking any strong drugs that affect liver enzymes.
Select...
I cannot receive medications through an IV.
Select...
I have a history of specific lung conditions or signs of lung inflammation on a recent chest CT.
Select...
I have been treated with cabozantinib before.
Select...
I have been treated with CD137 agonists and immune checkpoint inhibitors before.
Select...
I have a history of certain infectious diseases.
Select...
I have a condition that prevents my body from absorbing nutrients properly.
Select...
I have serious heart problems.
Select...
I haven't taken any immunosuppressive drugs in the last 2 weeks.
Select...
I cannot swallow pills.
Select...
I have a serious stomach or intestine condition that could lead to bleeding or a tear.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ defined as the percentage of patients with partial (pr) or complete response (cr) as best overall response according to recist 1.1 by investigator assessment up to 21 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~defined as the percentage of patients with partial (pr) or complete response (cr) as best overall response according to recist 1.1 by investigator assessment up to 21 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Overall Response Rate
Secondary study objectives
"Number of Participants with TreatmentRelated Adverse Events as Assessed by CTCAE version 5.
Duration of response (DOR)
Objective response rate (ORR)
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CabozantinibExperimental Treatment3 Interventions
Eligible patients will be enrolled and receive treatment with
* Cycle 1-4 (cycles of 21 days)
* Cabozantinib predetermined protocol dosage po daily
* Nivolumab predetermined protocol dosage via IV every 3 weeks
* Ipilimumab predetermined protocol dosage via IV every 3 weeks
* After the first four cycles of therapy,
* Cabozantinib determined protocol dosage po daily
* Nivolumab predetermined protocol dosage via IV every 3 weeks (cycles of 28 days)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
2020
Completed Phase 2
~1760
Ipilimumab
2014
Completed Phase 3
~3140
Nivolumab
2014
Completed Phase 3
~5220
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Renal Cell Carcinoma (RCC) include Tyrosine Kinase Inhibitors (TKIs) and Immune Checkpoint Inhibitors (ICIs). TKIs, like Cabozantinib, inhibit enzymes that promote cancer cell growth and angiogenesis, thereby slowing tumor progression.
ICIs, such as Nivolumab and Ipilimumab, enhance the immune system's ability to target and destroy cancer cells by blocking inhibitory proteins on immune cells. This dual approach is significant for RCC patients as it combines direct inhibition of tumor growth with an enhanced immune response, offering a comprehensive strategy to manage advanced or metastatic RCC.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.Immunotherapy in kidney cancer: the past, present, and future.Nivolumab for the treatment of cancer.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.Immunotherapy in kidney cancer: the past, present, and future.Nivolumab for the treatment of cancer.
Find a Location
Who is running the clinical trial?
Bradley A. McGregor, MDLead Sponsor
2 Previous Clinical Trials
39 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,680 Previous Clinical Trials
4,125,022 Total Patients Enrolled
ExelixisIndustry Sponsor
120 Previous Clinical Trials
19,859 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't taken cancer drugs or tyrosine kinase inhibitors in the last 4 weeks.I have a bleeding disorder not caused by blood thinners.I have had a previous transplant of an organ or stem cells from a donor.You have a history of autoimmune disease.My organ and bone marrow functions are normal.I am not taking any strong drugs that affect liver enzymes.I cannot receive medications through an IV.I have a history of specific lung conditions or signs of lung inflammation on a recent chest CT.I have been treated with cabozantinib before.I will have a new tumor biopsy before starting treatment unless it's unsafe.I am 18 years old or older.I have been treated with CD137 agonists and immune checkpoint inhibitors before.I agree to use birth control during the study.You have more than 1.5 grams of protein in your urine over a 24-hour period.I have a history of certain infectious diseases.I am fully active and can carry on all pre-disease activities without restriction.You have a disease that can be measured using a specific set of guidelines.I have a condition that prevents my body from absorbing nutrients properly.I have serious heart problems.My kidney cancer cannot be removed by surgery and has spread.I haven't taken any immunosuppressive drugs in the last 2 weeks.I cannot swallow pills.I have a serious stomach or intestine condition that could lead to bleeding or a tear.I have received treatments for my condition before.
Research Study Groups:
This trial has the following groups:- Group 1: Cabozantinib
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger